Percheron Therapeutics Limited has released a press release.
Company Update
Filed with ASX ·
On 6ix: 6ix.com/news/company-update-298
6ix hasn’t read this filing yet.
Percheron Therapeutics Limited on 6ix
Earlier from Percheron Therapeutics
- Positive Results Achieved from ATL1103 Higher Dose Study
- ATL1103 Granted Orphan Drug Designation in Europe
- ATL1102 for Multiple Sclerosis - Update
- Antisense Technology Update
- Company Strategy Update
Later from Percheron Therapeutics
- ATL1103 Higher Dose Study
- Capital Management Initiatives - Update
- ATL1102 for Multiple Sclerosis - Progress Update
- Bonus and New Options Offer Prospectus
- Appendix 3C
Follow Percheron Therapeutics into a list and get an email when it puts out news.
Follow Percheron Therapeutics